Charlie Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual intensive outpatient mental health treatment for adolescents and young adults, Bozeman MT, raised $55M+. Addresses crisis-level care gaps via virtual IOP.
About
Charlie Health is a Bozeman, Montana-based virtual mental health company founded in 2020 that provides intensive outpatient program (IOP) care for adolescents, young adults, and families experiencing mental health crises. The company has raised over $55 million and targets the significant care gap between inpatient psychiatric hospitalization and standard outpatient therapy — a level of care that has historically been difficult to access, particularly outside major urban centers.\n\nCharlie Health's virtual IOP model delivers nine or more hours of structured group and individual therapy per week through a telehealth platform, allowing clients to receive high-intensity care from home while maintaining school or work routines. The clinical approach combines dialectical behavior therapy (DBT), cognitive behavioral therapy (CBT), and trauma-informed care, with treatment teams including licensed therapists, psychiatrists, and care coordinators. Programs are designed for adolescents aged 11 to 17 and young adults aged 18 to 26 presenting with depression, anxiety, trauma, self-harm, and suicidality.\n\nThe company accepts insurance from most major carriers, a deliberate strategic choice to reach underserved populations who cannot afford self-pay intensive treatment. Charlie Health's telehealth delivery model gives it geographic reach into rural and suburban communities where brick-and-mortar IOPs are scarce, positioning the company as an infrastructure solution for the adolescent mental health crisis that intensified during the COVID-19 pandemic.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.